Search

Your search keyword '"Slotman, Berend J."' showing total 46 results
Start Over Author "Slotman, Berend J."
46 results on '"Slotman, Berend J."'

1. Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol

Author

Civil, Yasmin A., Oei, Arlene L., Duvivier, Katya M., Bijker, Nina, Meijnen, Philip, Donkers, Lorraine, Verheijen, Sonja, van Kesteren, Zdenko, Palacios, Miguel A., Schijf, Laura J., Barbé, Ellis, Konings, Inge R. H. M., -van der Houven van Oordt, C. Willemien Menke, Westhoff, Paulien G., Meijer, Hanneke J. M., Diepenhorst, Gwen M. P., Thijssen, Victor, Mouliere, Florent, Slotman, Berend J., van der Velde, Susanne, and van den Bongard, H. J. G. Desirée

Published
2023
Full Text
View/download PDF

4. Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia

Author

Slotman, Berend J., Clark, Mary Ann, Özyar, Enis, Kim, Myungsoo, Itami, Jun, Tallet, Agnès, Debus, Jürgen, Pfeffer, Raphael, Gentile, PierCarlo, Hama, Yukihiro, Andratschke, Nicolaus, Riou, Olivier, Camilleri, Philip, Belka, Claus, Quivrin, Magali, Kim, BoKyong, Pedersen, Anders, van Overeem Felter, Mette, Kim, Young Il, Kim, Jin Ho, Fuss, Martin, and Valentini, Vincenzo

Published
2022
Full Text
View/download PDF

14. Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial - a study protocol

Author

Civil, Yasmin A., primary, Oei, Arlene L., additional, Duvivier, Katya M., additional, Bijker, Nina, additional, Meijnen, Philip, additional, Donkers, Lorraine, additional, Verheijen, Sonja, additional, Kesteren, Zdenko van, additional, Palacios, Miguel A., additional, Schijf, Laura J., additional, Barbé, Ellis, additional, Konings, Inge R.H.M., additional, Oordt, C. Willemien Menke-van der Houven van, additional, Westhoff, Paulien G., additional, Meijer, Hanneke J.M., additional, Diepenhorst, Gwen M.P., additional, Thijssen, Victor, additional, Mouliere, Florent, additional, Slotman, Berend J., additional, Velde, Susanne van der, additional, and Bongard, H.J.G. Desirée van den, additional

Published
2023
Full Text
View/download PDF

18. Treatment patterns for adrenal metastases using surgery and SABR during a 10-year period

Author

van Vliet, Claire, primary, Dickhoff, Chris, additional, Bahce, Idris, additional, Engelsman, Anton F., additional, Hashemi, Sayed M.S., additional, Haasbeek, Cornelis J.A., additional, Bruynzeel, Anna M.E., additional, Palacios, Miguel A., additional, Becker-Commissaris, Annemarie, additional, Slotman, Berend J., additional, Senan, Suresh, additional, and Schneiders, Famke L., additional

Published
2022
Full Text
View/download PDF

19. Impact of Daily Plan Adaptation on Organ-At-Risk Normal Tissue Complication Probability for Adrenal Lesions undergoing Stereotactic Ablative Radiation Therapy: NTCP advantages of adaptive MR-guided adrenal SABR

Author

Chen, Hanbo, Schneiders, Famke L, M E Bruynzeel, Anna, Lagerwaard, Frank J, van Sornsen de Koste, John R, Cobussen, Paul, Bohoudi, Omar, Slotman, Berend J, Louie, Alexander V, Senan, Suresh, Radiation Oncology, and CCA - Cancer Treatment and quality of life

Abstract

Introduction: Stereotactic ablative radiotherapy (SABR) can achieve good local control for metastatic adrenal lesions. Magnetic resonance (MR)-guidance with daily on-table plan adaptation can augment the delivery of SABR with greater dose certainty. The goal of this study was to quantify the potential clinical benefit MR-guided daily-adaptive adrenal SABR using the normal tissue complication probability (NTCP) framework. Methods: Patients treated with adrenal MR-guided SABR at a single institution were retrospectively reviewed. Lyman-Kutcher-Burman NTCP models were used to calculate the NTCP of upper abdominal organs-at-risk (OARs) at simulation and both before and after daily on-table plan adaptation. Differences in OAR NTCPs were assessed using signed-rank tests. Potential predictors of the benefits of adaptation were assessed by linear regression. Results: Fifty-two adrenal MR-guided SABR courses were analyzed. The baseline simulation plan underestimated the absolute stomach NTCP by 10.0% on average (95% confidence interval: 4.7–15.2%, p < 0.001). Daily on-table adaptation lowered absolute NTCP by 8.7% (4.2–13.2%, p < 0.001). The most significant predictor of the benefits of adaptation was lesion laterality (p = 0.018), with left-sided lesions benefitting more (13.3% [6.3–20.4%], p < 0.001) than right-sided lesions (2.1% [−1.6–5.7%], p = 0.25). Sensitivity analyses did not change the statistical significance of the findings. Conclusion: NTCP analysis revealed that patients with left adrenal tumors were more likely to benefit from MR-guided daily on-table adaptive SABR using current dose/fractionation regimens due to reductions in predicted gastric toxicity. Right-sided adrenal lesions may be considered for dose escalation due to low predicted NTCP.

Published
2021

31. Survival of patients with ovarian cancer: apart from stage and grade, tumor progesterone receptor content is a prognostic indicator

Author

Slotman, Berend J., Nauta, Jos J.P., and Rao, B. Ramanath

Subjects
Ovarian cancer -- Identification and classification, Hormones, Sex -- Measurement, Ovarian cancer -- Patient outcomes, Ovarian cancer -- Prognosis, Hormone receptors -- Measurement, Health
Abstract

Many cancer cells have receptors for sex hormones on their cell surfaces. In the cases of breast cancer and cancer of the endometrium (the lining of the uterus), the presence or absence of receptors for estrogen or progesterone has well-documented prognostic significance. Although some studies have examined the prognostic value of sex hormone receptors on ovarian cancer cells, the small number of patients or a superficial statistical analysis prevents useful conclusions from being drawn. To rectify this situation, a Cox proportional hazards model was used to analyze the data on sex hormone receptors, and other prognostic variables, in 100 patients with primary ovarian cancer. The patients' tumors were analyzed for the presence of estrogen receptors, progesterone receptors, and androgen receptors (androgens, of course, are male sex hormones, which are also present in smaller amounts in women). The presence of estrogen receptors on the tumor cells did not correlate with survival. However, both the presence of progesterone and androgen receptors correlated with significantly better survival. Of 100 patients, 10 were negative for both progesterone and androgen receptors; all 10 died of their disease. Analysis revealed that tumor grade, tumor stage, and progesterone receptor status were independent predictors of survival. Although androgen receptor status was correlated with survival, it was also correlated with other prognostic variables and thus is not an independent factor. The relative risk of patients lacking progesterone receptors on their ovarian tumor cells was 2.3 times that of patients with progesterone receptors. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1990

34. Synergism between cisplatin and radiotherapy in an in vitro prostate tumor cell line

Author

Geldof, Albert A., Kruit, Adrian, Newling, Don W.W., Slotman, Berend J., Urology, CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, Radiation Oncology, CCA - Clinical Therapy Development, and CCA - Cancer Treatment and quality of life

Abstract

Background: A combination of local irradiation and systemic cytotoxic treatment could improve therapeutic efficacy in metastatic prostate cancer. Radiosensitization can augment the treatment response to standard doses of radiation or enable lower treatment doses to be given; thus decreasing possible side effect. Intracellular glutathione has been implicated in the mechanism of such radio- sensitizing effects. Materials and Methods: In the present study, R3327-MATLyLu prostate tumor cells were treated with cisplatin (0.0325 μM, 0.1625 μM, 0.325 μM and control '0 μM') in combination with irradiation (2, 4, 6, 8 Gy and control '0 Gy'). The survival of clonogenic tumor cells in agar was determined. In another experiment the irradiation was carried out after a 3 hours pretreatment with cisplatin concentrations (1.63 μM, 3.25 μM, 6.5 μM and control '0 μM') both in the presence and absence of Glutathione. Results: In both experimental conditions the combination of cisplatin with irradiation yielded significant supra-additive treatment effects. Conclusions: The analysis of combination treatment effects, using two different methods confirmed the existence of synergism. The presence of a high level of extracellular glutathione did not alter the radiosensitization effects observed without glutathione, suggesting that the presence of glutathione may not be a major limiting factor in the radiosensitization effects observed in the investigations.

Published
1999

35. Prophylactic Cranial Irradiation in Extensive Disease Small-Cell Lung Cancer: Short-Term Health-Related Quality of Life and Patient Reported Symptoms—Results of an International Phase III Randomized Controlled Trial by the EORTC Radiation Oncology and Lung Cancer Groups

Author

Slotman, Berend J., primary, Mauer, Murielle E., additional, Bottomley, Andrew, additional, Faivre-Finn, Corinne, additional, Kramer, Gijs W.P.M., additional, Rankin, Elaine M., additional, Snee, Michael, additional, Hatton, Matthew, additional, Postmus, Pieter E., additional, Collette, Laurence, additional, and Senan, Suresh, additional

Published
2009
Full Text
View/download PDF

43. Radiosensitivity and TP 53, EGFR amplification and LOH10 analysis of primary glioma cell cultures.

Author

Gerlach, Bärbel, Harder, Anna H, Hulsebos, Theo J M, Leenstra, Sieger, Slotman, Berend J, Vandertop, W Peter, Hartmann, Karl-Axel, and Sminia, Peter

Abstract

Aim: Determination of in-vitro radiosensitivity and genetic alterations of cell cultures derived from human glioma biopsy tissue and established glioma cell lines.Material and Methods: Fresh brain tumor specimens of six patients were processed to early passage cell cultures. In addition the cell lines D 384 and Gli 6 were used. Cell cultures were irradiated with doses from 2 to 10 Gy. Following irradiation, cell survival was determined by clonogenic assay and survival curves were generated. The surviving fractions after 2 Gy (SF2) and 4 Gy (SF4) were used as radiosensitivity parameters. Genetic analysis included determination of the mutational and loss of heterozygosity (LOH) status of TP 53 (exons 5-8), the LOH 10- and epidermal growth factor receptor gene (EGFR) amplification status.Results: The SF2 and SF4 values ranged from 0.54 to 0.88 (mean: 0.70) and from 0.13 to 0.52 (mean: 0.32), respectively. Genetic alterations were found in the Gli 6 cell line and in two primary cell cultures. The genetic profile of Gli 6 showed LOH but no TP 53 mutation, complete LOH 10 and no EGFR amplification. The VU 15 cell culture showed TP 53 mutation but no LOH 10 or EGFR amplification, while VU 24 showed incomplete LOH 10, EGFR amplification and no TP 53 mutation. In the other four cell cultures and D 384 cell line no genetic alterations were diagnosed. Histopathological classification of glioblastoma multiforme and/or genetic alterations resulted in lower radiosensitivity.Conclusion: In this small series of early passage glioma cell cultures low radiosensitivity and alterations in cell regulatory genes were seen. Further testing of biological behavior in larger series of patient-derived material is ongoing. [ABSTRACT FROM AUTHOR]

Published
2002

45. Impact of daily plan adaptation on organ-at-risk normal tissue complication probability for adrenal lesions undergoing stereotactic ablative radiation therapy.

Author

Chen H, Schneiders FL, Bruynzeel AME, Lagerwaard FJ, van Sörnsen de Koste JR, Cobussen P, Bohoudi O, Slotman BJ, Louie AV, and Senan S

Subjects
Humans, Organs at Risk, Probability, Retrospective Studies, Radiosurgery adverse effects, Radiotherapy Planning, Computer-Assisted
Abstract

Introduction: Stereotactic ablative radiotherapy (SABR) can achieve good local control for metastatic adrenal lesions. Magnetic resonance (MR)-guidance with daily on-table plan adaptation can augment the delivery of SABR with greater dose certainty. The goal of this study was to quantify the potential clinical benefit MR-guided daily-adaptive adrenal SABR using the normal tissue complication probability (NTCP) framework., Methods: Patients treated with adrenal MR-guided SABR at a single institution were retrospectively reviewed. Lyman-Kutcher-Burman NTCP models were used to calculate the NTCP of upper abdominal organs-at-risk (OARs) at simulation and both before and after daily on-table plan adaptation. Differences in OAR NTCPs were assessed using signed-rank tests. Potential predictors of the benefits of adaptation were assessed by linear regression., Results: Fifty-two adrenal MR-guided SABR courses were analyzed. The baseline simulation plan underestimated the absolute stomach NTCP by 10.0% on average (95% confidence interval: 4.7-15.2%, p < 0.001). Daily on-table adaptation lowered absolute NTCP by 8.7% (4.2-13.2%, p < 0.001). The most significant predictor of the benefits of adaptation was lesion laterality (p = 0.018), with left-sided lesions benefitting more (13.3% [6.3-20.4%], p < 0.001) than right-sided lesions (2.1% [-1.6-5.7%], p = 0.25). Sensitivity analyses did not change the statistical significance of the findings., Conclusion: NTCP analysis revealed that patients with left adrenal tumors were more likely to benefit from MR-guided daily on-table adaptive SABR using current dose/fractionation regimens due to reductions in predicted gastric toxicity. Right-sided adrenal lesions may be considered for dose escalation due to low predicted NTCP., (Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results